Clinical Study
Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice
Table 1
Patients’ features.
| | | Overall patients | Unresectable HCC | Patients treated with sorafenib | Patients untreated with sorafenib | | | Total number (%) | Total number (%) | Total number (%) | Total number (%) |
| | Number of patients | 38 | 25 (66) | 10 (40) | 15 (60) | | Sex | | | | | | Male/female | 30/8 | 19/6 | 8/2 | 11/4 | | Age, years | | | | | | Median | 74 | 74 | 73 | 74 | | Range | 58–86 | 63–85 | 63–80 | 65–85 | | Elderly | | | | | | ≥65 <75 years | 18 (47) | 12 (48) | 4 (40) | 8 (53) | | ≥75 years | 17 (45) | 11 (44) | 5 (50) | 6 (40) | | WHO performance status | | | | | | 0 | 10 (26) | 6 (24) | 4 (40) | 2 (13) | | 1 | 21 (55) | 13 (52) | 6 (60) | 7 (47) | | 2 | 6 (16) | 5 (20) | — | 5 (33) | | 3 | 1 (3) | 1 (4) | — | 1 (7) | | CIRS stage | | | | | | Primary | 2 (5) | 2 (8) | — | 2 (13) | | Intermediate | 8 (21) | 4 (16) | 2 (20) | 2 (13) | | Secondary | 28 (74) | 19 (76) | 8 (80) | 11 (73) | | Liver disease | | | | | | Hepatitis | 9 (24) | 5 (20) | 2 (20) | 3 (20) | | Cirrhosis | 24 (63) | 18 (80) | 7 (70) | 11 (73) | | Etiology | | | | | | HBV | 1 (3) | 1 (4) | 1 (10) | — | | HCV | 13 (34) | 9 (36) | 2 (20) | 7 (47) | | HBV + HCV | 1 (3) | — | — | — | | Alcoholic | 15 (39) | 10 (40) | 3 (30) | 7 (47) | | Idiopathic | 8 (21) | 3 (12) | 2 (20) | 1 (7) | | Complications | | | | | | Varices | 12 (31.5) | 8 (32) | 4 (40) | 4 (27) | | Thrombosis | 7 (18) | 5 (20) | 1 (10) | 4 (27) | | Splenomegaly | 14 (37) | 12 (48) | 6 (60) | 6 (40) | | Laboratory tests | | | | | | Thrombocytopenia | 6 (16) | 5 (20) | 3 (30) | 2 (13) | | Hypertransaminasemia | 22 (58) | 19 (76) | 7 (70) | 12 (80) | | Cholestasis | 24 (63) | 21 (84) | 10 (10) | 11 (73) | | Hyperbilirubinemia | 11 (29) | 11 (44) | 5 (50) | 6 (40) | | Number of involved sites | | | | | | 1 | 24 (63) | 11 (44) | 4 (40) | 7 (47) | | ≥2 | 14 (37) | 14 (56) | 6 (60) | 8 (53) | | Sites of metastases | | | | | | Lung | 3 (8) | 3 (12) | 1 (10) | 2 (13) | | Lymph nodes | 11 (29) | 11 (44) | 5 (50) | 6 (40) | | Bone | 3 (8) | 3 (12) | 2 (20) | 1 (7) | | Ascites | 9 (24) | 8 (32) | 3 (30) | 5 (33) | | Pleural effusion | 2 (5) | 2 (8) | — | 2 (13) | | Liver nodules | | | | | | Single | 9 (24) | 2 (8) | — | 2 (13) | | Multiple | 29 (76) | 23 (92) | 10 (100) | 13 (87) | | Diagnosis | | | | | | Clinical | 24 (63) | 19 (76) | 6 (60) | 13 (87) | | Histophatological | 14 (37) | 6 (24) | 4 (40) | 2 (13) | | αfetoprotein at DMT evaluation | | | | | | Negative | 17 (48) | 6 (24) | 2 (20) | 4 (27) | | Positive | 3 (8) | 4 (16) | 2 (20) | 2 (13) | | ≥200 ng/mL | 10 (26) | 13 (52) | 6 (60) | 7 (47) | | Unknown | 8 (21) | 2 (8) | — | 2 (13) | | Child-Pugh score at DMT evaluation | | | | | | A | 20 (53) | 11 (44) | 5 (50) | 6 (40) | | B | 11 (29) | 12 (48) | 5 (50) | 7 (47) | | C | 3 (8) | 2 (8) | — | 2 (13) | | Unknown | 4 (10) | — | — | — | | BCLC stage at DMT evaluation | | | | | | 0 | 2 (5) | — | — | — | | A | 9 (24) | 2 (8) | — | 2 (13) | | B | 10 (26) | 7 (28) | 3 (30) | 4 (27) | | C | 13 (34) | 13 (52) | 6 (60) | 7 (47) | | D | 4 (11) | 3 (12) | 1 (10) | 2 (13) | | DMT treatment choice | | | | | | Follow-up | 11 (29) | 2 (8) | — | 2 (13) | | Surgery | 1 (2) | — | — | — | | Biopsy | 3 (8) | 3 (12) | — | 3 (20) | | TACE | 5 (13) | 3 (12) | — | 3 (20) | | Sorafenib | 12 (32) | 12 (48) | 10 (100) | 2 (13) | | Best supportive care | 6 (16) | 5 (20) | — | 5 (33) | | Sorafenib treatment | | | | | | 800 mg/die | 3 (8) | 3 (30) | 3 (30) | — | | 600 mg/die | 3 (8) | 3 (30) | 3 (30) | — | | 400 mg/die | 4 (10.5) | 4 (40) | 4 (40) | — |
|
|
WHO: World Health Organization; CIRS: Cumulative Illness Rating Scale; TACE: transarterial chemoembolization; DMT: disease management team.
|
